Both YBX1 and PRMT5 have emerged as important therapeutic targets for several cancers including CRC and are thought to act upstream of cellular signaling pathways involved in tumorigenesis and cancer progression21, 28. This evidence concerns the gene PRMT5 and colorectal carcinoma.